0001415889-23-016754.txt : 20231219
0001415889-23-016754.hdr.sgml : 20231219
20231219185854
ACCESSION NUMBER: 0001415889-23-016754
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231215
FILED AS OF DATE: 20231219
DATE AS OF CHANGE: 20231219
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wingrove Theresa
CENTRAL INDEX KEY: 0001510720
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-17999
FILM NUMBER: 231498919
MAIL ADDRESS:
STREET 1: IMMUNOGEN, INC.
STREET 2: 830 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ImmunoGen, Inc.
CENTRAL INDEX KEY: 0000855654
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 042726691
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 830 WINTER ST
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: (781)895-0600
MAIL ADDRESS:
STREET 1: 830 WINTER ST
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: IMMUNOGEN INC
DATE OF NAME CHANGE: 19920703
4
1
form4-12192023_111248.xml
X0508
4
2023-12-15
0000855654
ImmunoGen, Inc.
IMGN
0001510720
Wingrove Theresa
C/O IMMUNOGEN, INC.
830 WINTER STREET
WALTHAM
MA
02451
false
true
false
false
SVP OF REGULATORY AFFAIRS
1
Common Stock
2023-12-15
4
M
0
27788
4.55
A
30599
D
Common Stock
2023-12-15
4
M
0
89657
5.32
A
120256
D
Common Stock
2023-12-15
4
S
0
117445
29.40
D
2811
D
Stock Option (right to buy)
4.55
2023-12-15
4
M
0
27788
0
D
2030-02-07
Common Stock
27788
35871
D
Stock Option (right to buy)
5.32
2023-12-15
4
M
0
89657
0
D
2032-02-04
Common Stock
89657
115273
D
Effected pursuant to a trading plan adopted on June 13, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.37 to $29.49, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
This option was granted on 2/7/2020 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.
This option was granted on 2/4/2022 and is exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.
/s/ Renee Lentini, Attorney-in-Fact
2023-12-19